Spotlighting New Sources for Personalized Neoantigen Treatment

Time: 3:30 pm
day: Day One


  • Overcoming the difficulties found in patients with low number of mutations by exploring  novel personalized cancer treatments that aren’t solely targeting neoepitopes arising from missense mutations
  • Discovering new sources of targetable epitopes to develop personalized cancer vaccines in patient populations with low mutational burden (low-TMB)
  • Exploring genomic rearrangement, splice variants and ERVs as potential new sources to be utilized in tomorrows’ personalised cancer vaccines